Overexpression of cannabinoid receptor CB2 may be a prognostic biomarker for NSCLC adenocarcinomas.
The nongovernmental organizations argued that patents for this CAR-T should never have been granted in the first place because the underlying technology is not novel.
First-line pembrolizumab plus chemotherapy prolonged survival among patients with advanced esophageal or esophagogastric junction cancer.
Compared with sunitinib alone, nivolumab plus cabozantinib therapy was associated with a 49% decreased risk for progression and 40% decreased risk for death.
Different patterns of rheumatic symptoms were observed in patients with rheumatic irAEs.
A new study examines the differences in access to novel therapies for European patients with cancer compared with patients in other geographic regions.
Nivolumab plus chemotherapy prolonged survival of patients with advanced gastric, gastroesophageal junction, and esophageal cancers compared with chemotherapy.
Currently, fulvestrant plus palbociclib is approved by the FDA in the metastatic breast cancer setting only following disease progression on endocrine therapy.
This phase 3 study compared endocrine therapy with or without abemaciclib in patients with high-risk, early-stage, hormone receptor-positive, HER2-negative breast cancer.
Loss of the tumor suppressor PTEN, a negative prognostic factor in metastatic CRPC, is associated with dysregulation of the PI3K–AKT–mTOR pathway.
Data from the CCC19 registry were evaluated to uncover risk factors associated with increased 30-day mortality in patients with cancer infected with COVID-19.
Treatment of some types of rare sarcomas with pembrolizumab resulted in durable clinical benefit for some patients. Partial response rates were highest in alveolar soft-part sarcoma.
Black and Hispanic patients were more likely to have COVID-19 but less likely to have an increase in telehealth visits.
Durvalumab plus tremelimumab added to chemotherapy did not improve survival or response in metastatic pancreatic cancer, according to results of a phase 2 trial.
There was no benefit to adding palbociclib to adjuvant endocrine therapy for treatment of early HR+, HER2- breast cancer vs endocrine therapy alone, according to a results from PALLAS.
Neoadjuvant atezolizumab plus standard-of-care chemotherapy improved the pCR rate among women with early TNBC, regardless of PD-L1 positivity.
This was a planned interim analysis of a phase 3 study comparing lorlatinib and crizotinib as a frontline treatment for patients with ALK-positive NSCLC.
Analysis suggests osimertinib lowers the risk of CNS recurrence in patients with completely resected EGFR-mutated NSCLC.
“Immunotherapy-alone [patients] had similar rates of death compared with those not on treatment within the past year,” Dr Wise-Draper emphasized.
Anticancer treatment modifications resulted in posttraumatic stress among patients and their health care providers.